Amp Volatility Score
Catalyst Info & Data Links
TITLE: INOpulse for PH-COPD phase 3 trial
WHAT IS THE NEXT CATALYST EVENT?
Phase 3 trial
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
05-16-2018 Bellerophon to Present Positive Results from Phase 2 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease at the American Thoracic Society 114th International Conference
MECHANISM OF ACTION
COPD is a chronic progressive disease caused by chronic inflammation and destruction of the airways and lung tissue. While COPD is primarily a respiratory disease, the chronic exposure to toxins in tobacco smoke and resulting lack of oxygen may cause changes in the pulmonary circulation, resulting in chronic pulmonary vasoconstriction and pulmonary hypertension.
See more info here
Updated by MV
#COPD #BLPH #Inopulse #Lungdisease
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post